T1DType 1 Diabetes
References in periodicals archive ?
The short-term and long-term data from DEPICT-1, along with the short-term data from DEPICT-2, indicated that the product, when given as an oral adjunct to adjustable insulin in patients with inadequately-controlled T1D, indicated significant and clinically-relevant reductions from baseline in HbA1c, weight and total daily insulin dose at 24 and 52 weeks, compared to placebo, at both 5 mg and 10 mg doses.
This month Malaika has been raising awareness of T1D in school and on Pearl FM, where she a guest speaker.
Within these high-risk groups there were marked differences in both the likelihood of developing T1D and the average age of diagnosis.
IDRF supports researchers all over the world, but never before have we been able to analyze their data comprehensively, in a way that can tell us why some children who are at risk get T1D and others do not.
T1D is a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels.
The 12 organisations joining #Coverage2Control are: American Association of Clinical Endocrinologists, American Association of Diabetes Educators, Children with Diabetes, College Diabetes Network, Diabetes Patient Advocacy Coalition, Diabetes Sisters, diaTribe Foundation, Endocrine Society, National Diabetes Volunteer Leadership Council, T1D Exchange, Team Type 1 Foundation and The Leona M.
Scientists at the University of Copenhagen looking to provide a cell therapy for T1D have identified a unique cell surface protein present on human pancreatic precursor cells.
This year's theme was "Hope in Old Havana: Leaving T1D in the Past.
The application of this trial's results to clinical practice can benefit people with T1D by reducing their burden of multiple daily fingersticks when using CGM and can enhance the cost-effectiveness of CGM therapy by reducing the number of daily BGM test strips," they wrote.
Caladrius Biosciences product candidate CLBS03 (autologous expanded polyclonal regulatory T cells, or Tregs) was granted Fast Track designation by the FDA for the treatment of type 1 diabetes mellitus (T1D), making it the first known therapeutic candidate for treatment of T1D to receive the designation.
An autoimmune destructive process, which plays a central role in the development of T1D, is facilitated by the subject's own genetic susceptibility and by non-genetic factors.
1] Recent work has also revealed seven shared non-human leukocyte antigen loci associated with CD and T1D.